Treatment Goals and Frontline Strategies in Multiple Myeloma

In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life. Dr. Baljevic explains that treatment aims to prevent myeloma from shortening patients' lives while preserving quality of life, with treatment intensity tailored to individual patient needs. He highlights the potential for durable, treatment-free responses and the possibility of cure in a subset of patients following advances in T-cell redirecting therapies, including CAR T-cell therapy. The discussion also addresses the current role of quadruplet-based therapy, autologous stem cell transplantation, consolidation, and maintenance in transplant-eligible patients. For transplant-ineligible patients, Dr. Baljevic considers whether increasingly effective bispecific therapies could support more limited-duration treatment approaches. The segment concludes by emphasizing the rapidly changing multiple myeloma treatment landscape and the need to continually adapt frontline and early-relapse strategies as new clinical evidence emerges.